Implementation of IT supported standardization of individualized hydrocortisone management for treatment of patients with adrenal insufficiency

被引:0
|
作者
Chakravarthy, Varshini [1 ]
Barger, Katie [2 ]
Gonsalves, Rob [2 ]
Shaibi, Gabriel Q. [2 ]
Vaidya, Vinay [3 ]
Kapadia, Chirag [2 ]
Newbern, Dorothee [2 ]
机构
[1] Phoenix Childrens, Pediat Endocrinol & Diabet, 1920 E Cambridge Ave Suite 301, Phoenix, AZ 85006 USA
[2] Phoenix Childrens, Pediat Endocrinol & Diabet, Phoenix, AZ USA
[3] Phoenix Childrens, Dept Informat Technol, Phoenix, AZ USA
来源
关键词
adrenal insufficiency; hydrocortisone; standardization; quality improvement; stress dosing;
D O I
10.1515/jpem-2023-0313
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Hydrocortisone stress dosing guidelines for children with adrenal insufficiency (AI) recommend a wide range of acceptable stress doses. This has led to variability in dosing recommendations resulting in confusion among endocrine, non-endocrine providers and patient families. This quality improvement project sought to standardize documentation and hydrocortisone stress dosing within our pediatric endocrine division to optimize communication regarding AI management.Methods Plan-Do-Study-Act (PDSA) cycle one aimed to address documentation of components important in AI management including body surface area (BSA), home daily dose, home stress dose, in-patient stress dose, procedure dose and crisis dose using a smart phrase within the electronic health record (EHR). To automate the process, PDSA cycle two introduced two smart buttons within the endocrine notes. PDSA cycle three focused on standardizing hydrocortisone stress doses.Results Initial documentation targets were met for all AI management components except for the crisis dose. The second target was only met for the home stress dose. Implementing the smart buttons aided in reaching the second target for home daily and home stress doses. Dose standardization targets were achieved in all categories except for the on-going crisis dose. A follow up survey after an in-service for non-endocrine providers showed increased knowledge of locating hydrocortisone stress dosing recommendations within the EHR.Conclusions With the assistance of technology, this quality improvement project ultimately enhanced communication through the standardization of documentation and individualized hydrocortisone stress dosing for children with AI. Although not all secondary targets were met, there was meaningful improvement in documentation and stress dose standardization compliance.
引用
收藏
页码:1175 / 1180
页数:6
相关论文
共 50 条
  • [21] Improvement in quality of life (QoL) in patients with adrenal insufficiency following treatment with modified release hydrocortisone therapy.
    Dineen, R.
    Ahmed, K. S.
    Frizelle, I
    Gunness, A.
    Garrahy, A.
    Hannon, A. M.
    Smith, D.
    McDermott, J.
    Healy, M. L.
    Agha, A.
    Pazderska, A.
    Gibney, J.
    Thompson, C. J.
    Behan, L. A.
    Sherlock, M.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2019, 188 : S224 - S224
  • [22] Diagnosis and Management of Adrenal Insufficiency in Hospitalized Patients
    Reddy, Pramod
    AMERICAN JOURNAL OF THERAPEUTICS, 2021, 28 (02) : E238 - E244
  • [23] Infacort®, Oral Hydrocortisone Granules with Taste Masking for the Treatment of Neonates and Infants with Adrenal Insufficiency
    Whitaker, Martin
    Digweed, Dena
    Spielmann, Sarah
    Huatan, Hiep
    Eckland, David
    Johnson, Trevor
    Tucker, Geoff
    Blankenstein, Oliver
    Krude, Heiko
    Ross, Richard J.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [24] Acute psychosis in the course of treatment of acute adrenal crisis with hydrocortisone in the patient with secondary adrenal insufficiency - a case study
    Brykalski, Jan
    Papierska, Lucyna
    Zaluska, Maria
    PSYCHIATRIA POLSKA, 2015, 49 (04) : 673 - 681
  • [25] INCREASED SERUM OSTEOPROTEGERIN IN PATIENTS WITH PRIMARY ADRENAL INSUFFICIENCY RECEIVING CONVENTIONAL HYDROCORTISONE SUBSTITUTION
    Fichna, M.
    Zurawek, M.
    Fichna, P.
    Gryczynska, M.
    Nowak, J.
    Ruchala, M.
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2012, 63 (06): : 677 - 682
  • [26] Bone safety of dual-release hydrocortisone in patients with autoimmune primary adrenal insufficiency
    Bioletto, Fabio
    Barale, Marco
    Parasiliti-Caprino, Mirko
    Giannelli, Jacopo
    Campioni, Lorenzo
    Cappiello, Vincenzo
    Di Carlo, Maria Chiara
    Ghigo, Ezio
    Procopio, Massimo
    Giordano, Roberta
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [27] Mortality Risk in Patients With Adrenal Insufficiency Using Prednisolone or Hydrocortisone: A Retrospective Cohort Study
    Ngaosuwan, Kanchana
    Johnston, Desmond G.
    Godsland, Ian F.
    Cox, Jeremy
    Majeed, Azeem
    Quint, Jennifer K.
    Oliver, Nick
    Robinson, Stephen
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (08): : 2242 - 2251
  • [28] Hydrocortisone for adrenal insufficiency does not lead to increased insulin requirements in critically injured patients
    Pappas, Peter A.
    Lube, Matthew W.
    Lentz, Scott
    CRITICAL CARE MEDICINE, 2007, 35 (12) : A63 - A63
  • [29] Emergency management of acute adrenal insufficiency (adrenal crisis) in adult patients
    Arlt, Wiebke
    ENDOCRINE CONNECTIONS, 2016, 5 (05) : G1 - G3
  • [30] Once-daily, modified-release hydrocortisone in patients with adrenal insufficiency reply
    Isidori, Andrea M.
    Hasenmajer, Valeria
    Venneri, Mary Anna
    LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (04): : 270 - 271